Recursion's Strategic Acquisition
Recursion Pharmaceuticals, a leading biotech firm known for its use of artificial intelligence to discover new drug candidates, has announced its agreement to acquire Exscientia, a smaller competitor, for $688 million in an all-stock transaction. This move highlights the growing trend of leveraging AI to revolutionize drug development.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
